Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
ATOS Stock Chart & Stats
$5.83
>-$0.01(-0.49%)
At close: 4:00 PM EST
$5.83
>-$0.01(-0.49%)
Day’s Range― - ―
52-Week Range$1.95 - $19.33
Previous CloseN/A
Volume314.80K
Average Volume (3M)1.16M
Market Cap
$20.05M
Enterprise Value-$14.62M
Total Cash (Recent Filing)$31.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Aug 17, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.37
Shares Outstanding9,974,998
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap-0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.83K
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$22.00Price Target Upside277.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no reported debt meaningfully reduces near-term fixed obligations and interest risk, preserving optionality for a clinical-stage biotech. This structural strength lowers financing stress and gives management flexibility on timing and choice of capital raises to fund trials and operations.
IP Clarity For Z-endoxifenSettlement removing PTAB challenges and clarifying field/formulation allocations reduces legal overhang and strengthens exclusivity for Z-endoxifen. Clearer IP rights support long-term development plans, improve bargaining position for partnerships or licensing, and lower execution risk for commercialization.
Governance And Capital-structure FlexibilityShareholder approvals reinforced board continuity and governance oversight while authorizing a reverse split provides a structural tool to manage listing compliance and share price. Combined with auditor ratification, this preserves managerial options and supports orderly capital-structure actions.
Bears Say
No Revenue; Widening LossesThe absence of product revenue and growing operating losses reflect that the company remains purely clinical-stage without commercialization. Persistent losses shrink equity, necessitate repeated funding rounds, and increase execution risk if trial timelines or approvals slip, pressuring long-term viability.
Accelerating Cash BurnWorsening negative free cash flow indicates rising funding needs to sustain clinical programs. Accelerating burn amplifies dilution risk from future financings, constrains strategic choices, and can force unfavorable financing timing, hindering long-term program continuity if capital markets tighten.
Eroding Shareholders' EquityMaterial decline in equity over several years signals capital depletion from operating losses. A smaller equity cushion reduces resilience to adverse events, impairs leverage for borrowing or partnerships, and highlights poor capital efficiency that could limit long-term strategic flexibility.
Atossa Therapeutics News
ATOS FAQ
What was Atossa Therapeutics’s price range in the past 12 months?
Atossa Therapeutics lowest stock price was $1.95 and its highest was $19.33 in the past 12 months.
What is Atossa Therapeutics’s market cap?
Atossa Therapeutics’s market cap is $20.05M.
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 58 days.
How were Atossa Therapeutics’s earnings last quarter?
Atossa Therapeutics released its earnings results on May 08, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.99 by -$0.12.
Is Atossa Therapeutics overvalued?
According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued.
Does Atossa Therapeutics pay dividends?
Atossa Therapeutics does not currently pay dividends.
What is Atossa Therapeutics’s EPS estimate?
Atossa Therapeutics’s EPS estimate is -1.05.
How many shares outstanding does Atossa Therapeutics have?
Atossa Therapeutics has 9,974,998 shares outstanding.
What happened to Atossa Therapeutics’s price movement after its last earnings report?
Atossa Therapeutics reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.99. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Atossa Therapeutics?
Currently, no hedge funds are holding shares in ATOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
ATOS Stock 12 Month Forecast
Average Price Target
$22.00
▲(277.36% Upside)
Technical Analysis
Ownership Overview
2.17% Insiders
25.48% Mutual Funds
<0.01% Other Institutional Investors
68.77% Public Companies and
Individual Investors